Argus Investors' Counsel, Inc. Abb Vie Inc. Transaction History

Argus Investors' Counsel, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	BUY	$159.82 - $182.1 $217,195 - $247,473	1,359 New	1,359 $247,000
Q1 2019 Apr 16, 2019	SELL	$77.14 - $90.79 $385,237 - $453,405	-4,994 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$77.85 - $96.01 $56,207 - $69,319	722 Added 16.9%	4,994 $460,000
Q3 2018 Oct 16, 2018	BUY	$88.91 - $98.84 $54,768 - $60,885	616 Added 16.85%	4,272 $0
Q2 2018 Jul 19, 2018	BUY	$89.78 - $106.23 $328,235 - $388,376	3,656 New	3,656 $339,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Argus Investors' Counsel, Inc., based on Form 13F filings with the SEC.

Stay updated on Argus Investors' Counsel, Inc. with notifications on news.